MCL1 and cancer: Cytotoxic activity of sorafenib in human cancer cells has been ascribed to downregulation of anti-apoptotic proteins as Mcl-1 [20, 51]; accordingly, we observed that sorafenib downregulates the expression of Mcl-1 in all the three MPM TIC cultures, an event contributing to the proapoptotic activity of this drug.